Murepavadin is under clinical development by Spexis and currently in Phase I for Bronchiectasis. According to GlobalData, Phase I drugs for Bronchiectasis have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Murepavadin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Murepavadin overview
Murepavadin (POL-7080) is under development for the treatment of nosocomial pneumonia (Ventilator-associated and hospital-acquired pneumonia caused by Pseudomonas aeruginosa, cystic fibrosis, Pseudomonas aeruginosa infections. The drug candidate is an antibiotic which is administered as intravenous infusion and inhalation route. It targets the beta-barrel protein LptD, which is involved in the outer-membrane biogenesis of lipopolysaccharide. It is developed based on the protein epitope mimetics (PEM) technology platform. It was under development for the treatment of bronchiectasis and ventilator-associated bacterial pneumonia caused by Pseudomonas aeruginosa, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infection, bloodstream infection and complicated intra-abdominal infection.
Spexis overview
Spexis formerly Polyphor Ltd, is a biopharmaceutical company developing immuno-oncology medicines and antibiotics for treatment of cancer and respiratory diseases. The company’s pipeline product include coliFin treats chronic cystic fibrosis infections; inhaled murepavadin is for the treatment of chronic cystic fibrosis and non-cf bronchiectasis infections; lonodelestat targets neutrophil elastase inhibition. It markets its products under the brand name ColiFin, an inhaled therapeutic for cystic fibrosis. The company has offices in Allschwil, Switzerland and Boston, Massachusetts. Spexis is headquartered in Allschwil, Switzerland.
For a complete picture of Murepavadin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
